BRIEF — CHMP Recommends EU Approval Of Roche's Ocrevus For Children And Adolescents

Sept 18 (Reuters) — Roche Holding AG: Chmp Recommends Eu Approval Of Roche’s Ocrevus For Children And Adolescents With Relapsing Multiple Sclerosis Roche Holding Ag - Ema Chmp Recommends Approval Of Ocrevus Iv For Paediatric Rms Patients Aged 10 And Older Roche Holding Ag - Final Decision From European Commission On Ocrevus Approval Expected Soon Roche Holding Ag - Ocrevus Demonstrates Non-inferiority In Relapse Control And Superiority Over Fingolimod In Phase Iii Study Roche Holding Ag - Ocrevus Reduced Risk Of Relapses By 48% Compared With Fingolimod In Paediatric Ms Source text:... Further company coverage: ROPC.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)